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In the United States, an estimated 40,000 cases of rectal cancer are expected to occur in 2011. Incidence continues to decrease, as largely evidenced by detection and removal of precancerous lesions through screening. In contrast, in adults younger than 50 years with average risk in whom screening is not recommended, colorectal cancer incidence rates have been increasing by 1.6% per year since 1998. Once metastases are detected, the 5-year survival for colorectal cancer approaches a dismal 10% \[[@B1]\]. Colorectal cancer is unique from other solid tumors in that resection of isolated hepatic, peritoneal, or lung metastasis has curable potential in highly selected individuals \[[@B2]\]. However, scant literature exists on the incidence and management of isolated splenic metastasis in solid malignancies, including rectal cancer. This case illustrates the importance of post-treatment surveillance, highlights diagnostic and potential multi-modality treatment strategies, and discusses the pathogenesis and prognosis of this uncommon presentation in a young woman with rectal cancer.

Case Report {#sec1_2}
===========

A 22-year-old female with no significant medical history developed 6 months of hematochezia, which she presumed was secondary to bleeding hemorrhoids. She presented to her physician an additional 2 months after her symptoms progressed to fecal urgency and incomplete evacuation with bowel movements. Digital rectal examination revealed a palpable, nearly circumferential nodular mass, which was tethered to the vaginal apex. Endoscopic examination demonstrated an ulcerated rectal lesion located 10 cm from the anal verge. Notably polyps were absent. Computed tomography (CT) of the chest, abdomen, and pelvis revealed a lobulated, soft tissue mass in the rectum and perirectal fat stranding without lymphadenopathy or distant metastases. Endoscopic mucosal biopsies demonstrated the presence of a moderately differentiated adenocarcinoma, and concomitant endoscopic ultrasonographic examination suggested that the clinical tumor stage was T4N0. Pertinent laboratory values obtained at the time of the procedure included a carcinoembryonic antigen (CEA) level of 1.1 ng/ml (normal \<3.0 ng/ml). There was no family history of colorectal polyps or carcinoma, and the patient denied smoking or heavy alcohol use. She refused neoadjuvant chemoradiation therapy due to infertility concerns and was treated with neoadjuvant chemotherapy (FOLFOX, 5-fluorouracil, leucovorin, and oxaliplatin). This was followed by laparoscopic low anterior resection with total mesorectal excision. Histologic examination of the rectal mass confirmed a moderately differentiated adenocarcinoma, spanning 3.2 cm, with mucinous features (**fig. [1](#F1){ref-type="fig"}**). The malignant component infiltrated into the muscularis propria into the perirectal fat, extending to the mesorectal resection margin. Five of seventeen regional lymph nodes contained metastatic carcinoma with focal extracapsular extension (ypT3N2M0). The patient subsequently received adjuvant infusional 5-FU-based chemotherapy.

Nine months after completion of chemotherapy, surveillance imaging with positron emission tomography (PET/CT) imaging revealed an isolated 1-cm hypermetabolic lesion in the spleen with a standardized uptake value (SUV) of 6.4 (**fig. [2a](#F2){ref-type="fig"}** and b), compared to a SUV of 1.7 in the previous year\'s PET/CT. CEA and complete blood count were normal, and immunophenotyping by flow cytometry of peripheral blood was negative for lymphoproliferative disorder. The patient was otherwise asymptomatic with an ECOG performance status of 0. She received vaccination against encapsulated bacterial organisms and underwent a laparoscopic-assisted splenectomy. The spleen parenchyma contained a metastatic tumor deposit, histologically similar to the primary rectal carcinoma (**fig. [3](#F3){ref-type="fig"}**). The patient then received adjuvant chemotherapy (FOLFIRI, 5-fluorouracil, leucovorin, and irinotecan with bevacizumab) for 6 months. Subsequent surveillance scans have remained negative for recurrent disease at 52 months since completion of adjuvant chemotherapy.

Discussion {#sec1_3}
==========

Isolated metastatic involvement of the spleen is rare and sporadic and usually occurs in the setting of concomitant carcinomatosis. Solitary splenic metastases have been reported in lymphoma, melanoma, and gynecologic carcinoma but are a relatively atypical manifestation in rectal cancer \[[@B3], [@B4], [@B5], [@B6]\]. In most cases, solitary splenic metastases in rectal cancer are asymptomatic and are detected on imaging or as a result of rising CEA \[[@B7]\]. Berge \[[@B3]\] performed an autopsy study of 7,165 patients and found splenic metastases in only 4.4 and 1.6% of patients with colonic and rectal carcinoma, respectively; however, the incidence of solitary metastases was not reported.

To our knowledge, only three cases of rectal carcinoma with isolated splenic metastasis have been reported in the English literature \[[@B8]\]. The first case was that of a 69-year-old man with stage III rectal cancer who developed weight loss, anorexia, and abdominal symptoms related to splenomegaly \[[@B6]\]. The second patient was a 51-year-old female with stage II rectal cancer and solitary splenic metastasis that was detected as a result of increasing CEA levels \[[@B9]\]. The third patient, a 41-year-old male with rectal cancer treated 1 year prior with surgery, had the most catastrophic presentation, suffering a splenic rupture due to a massively enlarged spleen. Histology revealed diffuse involvement of the spleen with mucin-producing adenocarcinoma, and no other distant organs were involved \[[@B10]\]. These patients were treated with splenectomy, and subsequent chemotherapy was not administered. In our case, the young woman was asymptomatic and her CEA remained low at progression; the splenic lesion was identified on a surveillance PET/CT. We acknowledge that CT is the standard method for assessing recurrence, and the lesion may also have been seen on a CT with intravenous contrast.

The spleen as a site of metastases in rectal cancer is generally uncommon, presumably as a result of anatomic, functional, and immunologic factors. Carcinomas may spread to the spleen via three possible routes: hematogenous seeding from the splenic artery or vein, lymphovascular dissemination, and direct extension from the peritoneum. Vascular dissemination is least common, owing to the sharply angulated nature of the splenic and celiac arteries, the rhythmic contraction of the spleen, and a lack of afferent lymphatic vessels in the splenic parenchyma \[[@B11], [@B12]\]. Furthermore, the spleen is considered a hostile soil for neoplastic implantation, perhaps related to the immunologic surveillance function of the spleen \[[@B13]\]. The humoral substances and immunologically competent cells within the spleen have been hypothesized to destroy tumor cells as they reach the organ and decrease adherence of tumor cells to the basement membrane, respectively \[[@B14]\].

Management of this unique entity is not well established given the small amount of case reports available. The preferred surgical management appears to be splenectomy, supported by a survival benefit seen with metastasectomy in other cancers \[[@B7]\]. Moreover, post-metastasectomy chemotherapy has been shown to decrease recurrences and prolong survival in colorectal cancer patients with distant metastases \[[@B15]\]. Extrapolating from these data, administration of post-splenectomy chemotherapy can be a consideration in fit patients. Prognosis in rectal cancer patients with isolated solitary splenic metastasis is unknown, but the mean reported survival interval in a recent meta-analysis of 26 colorectal cancer patients with isolated splenic metastasis reached 19.5 months \[[@B7]\].

Conclusion {#sec1_4}
==========

This is a case of an isolated, solitary splenic metastasis from rectal carcinoma, a rare entity. Diagnosis can prove to be difficult as the majority of patients are asymptomatic, underscoring the importance of surveillance with both imaging and CEA levels. Management strategies are not conclusive and long-term prognosis is unknown. Our patient has been disease-free for nearly 5 years after splenectomy, and though it is unknown if post-splenectomy systemic chemotherapy has increased her overall survival, it could be considered in young patients with a good performance status.
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![The resected rectal cancer contained moderately differentiated malignant glands, many of which were distended with abundant mucin as seen at 100 HPF. Free pools of dissecting mucin were present within the tumor as well but accounted for less than 10% of the total tumor volume.](cro0004-0499-f01){#F1}

![**a** Coronal F-18 fluorodeoxyglucose (FDG) PET (left) and fused PET/CT (right) images demonstrate a hypermetabolic focus in the spleen, which corresponds to a low attenuation lesion on CT. The single white arrow indicates the splenic lesion. Pink arrows indicate physiologic urinary excretion of radiotracer within the renal calyces. **b** Transaxial F-18 FDG PET (left) and fused PET/CT (right) images at the level of the upper pole of the left kidney demonstrate FDG-avid mass within the posterior medial aspect of the midsection of the spleen.](cro0004-0499-f02){#F2}

![The spleen contained a metastatic tumor deposit within the parenchyma, unassociated with the overlying capsule. The tumor was histologically similar to the primary rectal carcinoma.](cro0004-0499-f03){#F3}
